Bristol Myers (BMY) announces FDA approves Nivolumab with chemotherapy for previously untreated hodgkin lymphoma
Context
Bristol Myers' approval of Nivolumab for treating previously untreated Hodgkin lymphoma is a significant milestone that could boost the company's oncology portfolio. This FDA approval enhances BMY's product offerings and may positively impact its share price due to increased expectations of revenue growth in the oncology segment. Traders should consider the potential market reaction, not only for BMY but also for competitors in the oncology space, as this sets a strong precedent for future approvals in similar therapeutics.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#BRISTOL-MYERS SQUIBB CO#BMY.US#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#BMY#US EQUITIES